Filana Therapeutics
FLNA
169 hedge funds and large institutions have $891M invested in Filana Therapeutics in 2021 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 59 increasing their positions, 38 reducing their positions, and 18 closing their positions.
228% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
95% more capital invested
Capital invested by funds: $456M → $891M (+$435M)
55% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 38
32% more funds holding
Funds holding: 128 → 169 (+41)
25% more call options, than puts
Call options by funds: $192M | Put options by funds: $153M
0.44% more ownership
Funds ownership: 26.66% → 27.1% (+0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$9.83M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$8.23M |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$6.65M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$6.53M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$6.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$12.7M |
| 2 |
Millennium Management
New York
|
-$9.91M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$8.81M |
| 4 |
BL
Bleichroeder LP
New York
|
-$6.7M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$5.68M |
FLNA Hedge Fund Activity: Q2 2021 in Review
169 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2021, worth a combined $891M — up 95% from $456M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new FLNA positions and 18 closed out — a net gain of 41 holders — while 59 added to existing stakes and 38 trimmed.
The largest buyer was State Street, adding an estimated $9.83M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $12.7M sold.
- 169 institutional investors held Filana Therapeutics (FLNA) as of Q2 2021, up from 128 in Q1 2021.
- Funds reported $891M of Filana Therapeutics stock for Q2 2021, up 95% quarter-over-quarter.
- 59 funds opened new Filana Therapeutics positions in Q2 2021 and 18 closed out, a net change of +41 holders.
- The largest Filana Therapeutics buyer in Q2 2021 was State Street, an estimated $9.83M added.
- The largest Filana Therapeutics seller in Q2 2021 was Marshall Wace North America, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2021.